…
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it provides digital advertising platform; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, and visualization solutions; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -10.10M | 4.15M | -6.84M | -14.18M | -6.58M |
| Minority interest | 0.39M | 2.75M | 3.23M | 1.42M | 1.42M |
| Net income | -10.21M | 4.05M | -6.85M | -14.18M | -6.60M |
| Selling general administrative | 14.17M | 9.96M | 5.49M | 13.18M | 3.34M |
| Selling and marketing expenses | 4.01M | 1.99M | 0.47M | 0.33M | 1.35M |
| Gross profit | 14.45M | 4.80M | -0.50M | -0.18M | -0.17M |
| Reconciled depreciation | 3.24M | 0.32M | 0.17M | 0.07M | 0.04M |
| Ebit | -13.78M | -8.20M | -7.38M | -14.42M | -6.82M |
| Ebitda | -11.99M | -22.23M | -7.89M | -14.46M | -6.78M |
| Depreciation and amortization | 1.80M | -14.03M | -0.50M | -0.04M | 0.04M |
| Operating income | -13.78M | -8.20M | -7.38M | -14.42M | -6.67M |
| Other operating expenses | 100.44M | 18.31M | 8.00M | 14.57M | 7.11M |
| Interest expense | -4.08M | 29.44M | 3.74M | 0.35M | 0.00M |
| Tax provision | 0.11M | 0.10M | 0.01M | -0.00M | 0.02M |
| Interest income | - | - | - | 0.14M | 0.15M |
| Net interest income | -2.31M | -0.35M | 0.20M | 0.10M | -0.05M |
| Extraordinary items | - | - | - | - | 0.00M |
| Non recurring | - | - | - | - | 0.00M |
| Other items | - | - | - | - | 0.00M |
| Income tax expense | 0.11M | 0.10M | 0.01M | -0.00M | 0.02M |
| Total revenue | 91.86M | 10.12M | 0.53M | 0.27M | 0.44M |
| Total operating expenses | 23.03M | 13.00M | 6.96M | 14.11M | 6.50M |
| Cost of revenue | 77.41M | 5.32M | 1.03M | 0.46M | 0.61M |
| Total other income expense net | 3.69M | 12.35M | 0.54M | 0.24M | 0.15M |
| Discontinued operations | - | - | - | - | 0.00M |
| Net income from continuing ops | -10.21M | 4.05M | -6.85M | -14.18M | -6.60M |
| Net income applicable to common shares | - | 6.79M | -4.33M | -14.18M | -6.60M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 63.90M | 97.65M | 59.73M | 32.34M | 13.33M |
| Intangible assets | 18.79M | 21.79M | 7.39M | - | - |
| Other current assets | 1.11M | 0.18M | 0.27M | 0.38M | 0.19M |
| Total liab | 31.46M | 42.96M | 8.30M | 6.14M | 5.20M |
| Total stockholder equity | 23.58M | 39.14M | 49.19M | 22.96M | 6.71M |
| Deferred long term liab | - | - | 0.84M | - | - |
| Other current liab | 3.04M | 10.41M | 4.90M | 3.25M | 2.67M |
| Common stock | - | - | - | 93.02M | 22.80M |
| Capital stock | 0.00M | 0.00M | 0.00M | 93.02M | 22.80M |
| Retained earnings | -101.61M | -85.59M | -74.19M | -80.98M | -76.66M |
| Other liab | - | - | 0.97M | 2.58M | 1.80M |
| Good will | 8.55M | 9.07M | 0.93M | - | - |
| Other assets | - | - | 0.84M | 1.15M | 4.09M |
| Cash | 9.36M | 20.07M | 24.02M | 22.36M | 7.04M |
| Total current liabilities | 29.27M | 37.63M | 6.64M | 3.51M | 3.37M |
| Current deferred revenue | 3.90M | 0.05M | 0.11M | 0.07M | 0.50M |
| Net debt | 0.43M | -9.93M | -22.41M | -22.26M | -6.88M |
| Short term debt | 9.08M | 6.74M | 0.93M | 0.06M | 0.12M |
| Short long term debt | 8.98M | 6.61M | 0.93M | - | - |
| Short long term debt total | 9.79M | 10.13M | 1.62M | 0.11M | 0.15M |
| Other stockholder equity | 113.08M | 111.52M | 110.76M | 0.20M | 48.07M |
| Property plant equipment | - | - | 0.08M | 0.37M | 0.27M |
| Total current assets | 31.67M | 52.26M | 31.65M | 24.05M | 8.28M |
| Long term investments | 3.77M | 13.13M | 18.84M | 6.19M | 4.76M |
| Net tangible assets | - | - | 40.87M | 22.39M | 6.69M |
| Short term investments | 3.18M | 4.99M | 3.31M | - | 0.00M |
| Net receivables | 15.64M | 25.23M | 1.69M | 0.26M | 0.07M |
| Long term debt | 0.23M | 2.88M | 0.69M | - | - |
| Inventory | 2.39M | 1.79M | 1.23M | 0.24M | 0.90M |
| Accounts payable | 13.25M | 20.42M | 0.70M | 0.14M | 0.07M |
| Accumulated other comprehensive income | 12.11M | 13.21M | 12.62M | 10.72M | 12.49M |
| Non currrent assets other | - | - | 0.84M | 1.15M | 5.05M |
| Non current assets total | 32.23M | 45.39M | 28.08M | 8.29M | 5.05M |
| Capital lease obligations | 0.57M | 0.64M | 0.00M | 0.11M | 0.15M |
| Long term debt total | - | - | - | - | 0.03M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -4.48M | -2.82M | -1.82M | -4.12M | 3.49M |
| Change to liabilities | - | -0.04M | 0.26M | 1.84M | 0.17M |
| Total cashflows from investing activities | - | -12.45M | -1.60M | -4.12M | 3.49M |
| Net borrowings | - | 0.43M | -0.05M | -0.05M | -0.05M |
| Total cash from financing activities | 5.41M | 19.15M | 22.95M | 3.16M | 8.63M |
| Change to operating activities | - | 1.18M | -0.01M | 0.20M | 0.12M |
| Net income | -10.10M | 4.15M | -6.84M | -14.18M | -6.58M |
| Change in cash | -3.96M | 1.66M | 15.33M | -3.59M | 7.80M |
| Begin period cash flow | 24.02M | 22.36M | 7.04M | 10.62M | 2.83M |
| End period cash flow | 20.07M | 24.02M | 22.36M | 7.04M | 10.62M |
| Total cash from operating activities | -5.66M | -5.25M | -6.14M | -2.69M | -4.22M |
| Issuance of capital stock | 12.57M | 18.72M | 22.99M | 0.00M | 8.63M |
| Depreciation | 3.24M | 0.32M | 0.17M | 0.07M | 0.04M |
| Other cashflows from investing activities | - | -1.47M | -1.47M | -4.06M | 3.50M |
| Dividends paid | -4.19M | - | -0.12M | - | 0.00M |
| Change to inventory | -0.56M | -0.55M | -0.47M | -0.82M | 0.02M |
| Change to account receivables | -7.84M | -0.24M | -0.07M | 0.00M | -0.01M |
| Sale purchase of stock | - | - | -22.95M | - | 8.63M |
| Other cashflows from financing activities | 1.75M | 1.92M | 0.12M | 3.20M | 3.49M |
| Change to netincome | - | -12.48M | -1.68M | 10.19M | 2.03M |
| Capital expenditures | 0.07M | 0.14M | 0.32M | 0.06M | 0.01M |
| Change in working capital | -1.12M | 0.12M | -0.28M | 1.22M | 0.31M |
| Stock based compensation | 0.79M | 2.36M | 1.39M | 0.26M | 0.16M |
| Other non cash items | 1.15M | 0.58M | 0.54M | 10.03M | -0.04M |
| Free cash flow | -5.73M | -5.39M | -6.47M | -2.76M | -4.23M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories |
-0.03 0.03% |
109.93 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-3.04 2.90% |
101.80 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-9.21 2.75% |
325.87 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-2.15 4.12% |
49.85 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it provides digital advertising platform; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, and visualization solutions; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.
| Name | Title | Year Born |
|---|---|---|
| Mr. Liron Carmel | Chief Exec. Officer | 1985 |
| Ms. Tali Dinar | Chief Financial Officer | 1971 |
| Dr. Yaron Silberman | Chief Exec. Officer of ScoutCam Ltd. | 1970 |
| Ilan Oren | Exec. Officer | NA |
| Mr. Liron Carmel | Chief Executive Officer | 1985 |
| Dr. Yaron Silberman | Chief Executive Officer of ScoutCam Ltd. | 1970 |
| Ilan Oren | Executive Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.